Yokohama City University Medical Center

Yokohama, Kanagawa Prefecture, JPN 232-0024

Showing 1 - 10of24studies

Short Bowel Syndrome Clinical Trial

Featured Trial

Short Bowel Syndrome Clinical Trial
NCT04627025 - Phase 3 - Interventional

The purpose of this study is to evaluate how the study drug, apraglutide, helps patients with SBS better manage their symptoms and may decrease the amount of PS needed as a result of improved gut health.

Recruiting

Male & Female

18 Years +


Urothelial Cancer Clinical Trial
Urothelial Cancer Clinical Trial
NCT03390504 - Phase 3 - Interventional

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at ...

Recruiting

Male & Female

18 Years +


Ulcerative Colitis Clinical Trial
Ulcerative Colitis Clinical Trial
NCT03518086 - Phase 3 - Interventional

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

Recruiting

Male & Female

18 - 80

Years old


Ulcerative Colitis Clinical Trial
Ulcerative Colitis Clinical Trial
NCT03519945 - Phase 3 - Interventional

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC).

Recruiting

Male & Female

18 - 80

Years old


Unresectable Cholangiocarcinoma Clinical Trial
Unresectable Cholangiocarcinoma Clinical Trial
NCT03656536 - Phase 3 - Interventional

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

Recruiting

Male & Female

18 Years +


Prostatic Neoplasms Clinical Trial
Prostatic Neoplasms Clinical Trial
NCT03767244 - Phase 3 - Interventional

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer re...

Recruiting

Male

18 Years +


Prostate Cancer Clinical Trial
Prostate Cancer Clinical Trial
NCT04100018 - Phase 3 - Interventional

The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.

Recruiting

Male

18 Years +


Neuromyelitis Optica Clinical Trial
Neuromyelitis Optica Clinical Trial
NCT04155424 - Phase 2 phase 3 - Interventional

The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).

Recruiting

Male & Female

2 - 17

Years old


Urinary Bladder Neoplasms Clinical Trial
Urinary Bladder Neoplasms Clinical Trial
NCT04172675 - Phase 2 - Interventional

The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive bladder cancer (NMIBC) who harbor fibroblast growth factor receptor (FGFR) mutations ...

Recruiting

Male & Female

18 Years +


Preeclampsia Clinical Trial
Preeclampsia Clinical Trial
NCT04182373 - Phase 3 - Interventional

The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of placebo.

Recruiting

Female

20 Years +


Connect with Us

No information available

Info

No information available

Yokohama, Kanagawa Prefecture, JPN 232-0024

No web site available

This website or its third-party tools use cookies, which are necessary for its functioning and required to achieve the purposes illustrated in the cookie policy.

You accept the use of cookies by clicking "I accept", closing or dismissing this notice, scrolling on this page, clicking a link or button on the page, or by continuing to browse otherwise.